{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:21:47Z","timestamp":1761895307361,"version":"3.44.0"},"reference-count":75,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1053\/j.seminhematol.2011.03.009","type":"journal-article","created":{"date-parts":[[2011,7,25]],"date-time":"2011-07-25T03:35:43Z","timestamp":1311564943000},"page":"227-239","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma: Where Are We Now and Which Way Should We Go?"],"prefix":"10.1053","volume":"48","author":[{"given":"Steven","family":"Le Gouill","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Guillaume","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Gastinne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2011.03.009_bib1","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0959-8049(01)00366-5","article-title":"A Danish population-based analysis of 105 mantle cell lymphoma patients: incidences, clinical features, response, survival and prognostic factors","volume":"38","author":"Andersen","year":"2002","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.seminhematol.2011.03.009_bib2","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/cncr.23608","article-title":"Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004","volume":"113","author":"Zhou","year":"2008","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2011.03.009_bib3","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/oxfordjournals.annonc.a059155","article-title":"Patterns of survival in mantle cell lymphoma","volume":"6","author":"Zucca","year":"1995","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2011.03.009_bib4","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/00000478-199207000-00001","article-title":"Mantle cell lymphoma","volume":"16","author":"Banks","year":"1992","journal-title":"Am J Surg Pathol"},{"key":"10.1053\/j.seminhematol.2011.03.009_bib5","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1182\/blood.V78.2.259.bloodjournal782259","article-title":"bcl-1, t(11;14), and mantle cell-derived lymphomas","volume":"78","author":"Raffeld","year":"1991","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.03.009_bib6","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1182\/blood.V76.7.1387.1387","article-title":"Genotypic characterization of centrocytic lymphoma: frequent rearrangement of the chromosome 11 bcl-1 locus","volume":"76","author":"Williams","year":"1990","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.03.009_bib7","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2010-04-189977","article-title":"Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era","volume":"11","author":"Perez-Galan","year":"2011","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.03.009_bib8","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nrc2230","article-title":"Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics","volume":"7","author":"Jares","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1053\/j.seminhematol.2011.03.009_bib9","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1200\/JCO.2005.04.164","article-title":"Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK)","volume":"23","author":"Ghielmini","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2011.03.009_bib10","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1200\/JCO.2008.16.8435","article-title":"Improvement of overall survival in advanced stage mantle cell lymphoma","volume":"27","author":"Herrmann","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2011.03.009_bib11","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","volume":"105","author":"Dreyling","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.03.009_bib12","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.03.009_bib13","first-page":"1275","article-title":"Sequential chemotherapy regimens followed by high-dose therapy with stem cell transplantation in mantle cell lymphoma: an update of a prospective study","volume":"89","author":"Lefrere","year":"2004","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2011.03.009_bib14","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/sj.leu.2402406","article-title":"Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study","volume":"16","author":"Lefrere","year":"2002","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2011.03.009_bib15","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/sj.bmt.1701400","article-title":"High-dose therapy with stem cell transplantation for mantle cell lymphoma: results and prognostic factors, a single center experience","volume":"22","author":"Milpied","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"10.1053\/j.seminhematol.2011.03.009_bib16","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1200\/JCO.1998.16.12.3803","article-title":"Hyper-CVAD and high-dose methotrexate\/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma","volume":"16","author":"Khouri","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2011.03.009_bib17","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1182\/blood-2008-10-184200","article-title":"Mature results of the MD Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma","volume":"113","author":"Tam","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.03.009_bib18","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1080\/10428190903026518","article-title":"Autologous and allogeneic stem cell transplantation: rising therapeutic promise for mantle cell lymphoma","volume":"50","author":"Tam","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2011.03.009_bib19","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/jnci\/djk152","article-title":"Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis","volume":"99","author":"Schulz","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1053\/j.seminhematol.2011.03.009_bib20","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1023\/A:1008380527502","article-title":"Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy","volume":"10","author":"Khouri","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2011.03.009_bib21","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3109\/10428194.2010.532893","article-title":"Mantle cell lymphoma: report of the 2010 Mantle Cell Lymphoma Consortium Workshop","volume":"52","author":"Williams","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2011.03.009_bib22","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/j.1365-2141.2009.07886.x","article-title":"The allogeneic graft-versus-cancer effect","volume":"147","author":"Ringden","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2011.03.009_bib23","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.3324\/haematol.11185","article-title":"Allogeneic transplantation in lymphoma: current status","volume":"92","author":"Schmitz","year":"2007","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2011.03.009_bib24","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1182\/blood-2003-04-1205","article-title":"Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma","volume":"102","author":"van Besien","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.03.009_bib25","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1182\/asheducation-2006.1.390","article-title":"Reduced-intensity regimens in allogeneic stem-cell transplantation for non-hodgkin lymphoma and chronic lymphocytic leukemia","author":"Khouri","year":"2006","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1053\/j.seminhematol.2011.03.009_bib26","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1007\/s002770000196","article-title":"Allogeneic bone marrow transplantation for refractory mantle cell lymphoma","volume":"79","author":"Kroger","year":"2000","journal-title":"Ann Hematol"},{"key":"10.1053\/j.seminhematol.2011.03.009_bib27","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/1096-8652(200009)65:1<75::AID-AJH14>3.0.CO;2-L","article-title":"Successful allogeneic stem-cell transplantation with prophylactic stepwise G-CSF primed-DLIs for relapse after autologous transplantation in mantle cell lymphoma: a case report and literature review on the evidence of GVL effects in MCL","volume":"65","author":"Sohn","year":"2000","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2011.03.009_bib28","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/sj.bmt.1701044","article-title":"Treatment of resistant mantle cell lymphoma with allogeneic bone marrow transplantation","volume":"21","author":"Adkins","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"10.1053\/j.seminhematol.2011.03.009_bib29","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1046\/j.1365-2141.1996.d01-1816.x","article-title":"Clinical and molecular remission after allogeneic blood cell transplantation in a patient with mantle-cell lymphoma","volume":"94","author":"Corradini","year":"1996","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2011.03.009_bib30","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/sj.bmt.1702567","article-title":"Patients with mantle-cell lymphoma relapsing after autologous stem cell transplantation may be rescued by allogeneic transplantation","volume":"26","author":"Martinez","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1053\/j.seminhematol.2011.03.009_bib31","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.bbmt.2007.04.013","article-title":"High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma","volume":"14","author":"Bloor","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1053\/j.seminhematol.2011.03.009_bib32","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1038\/sj.leu.2404822","article-title":"Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome","volume":"21","author":"Corradini","year":"2007","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2011.03.009_bib33","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.1200\/JCO.2003.05.501","article-title":"Nonablative allogeneic stem-cell transplantation for advanced\/recurrent mantle-cell lymphoma","volume":"21","author":"Khouri","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2011.03.009_bib34","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.bmt.1705074","article-title":"Donor lymphocyte infusions can result in sustained remissions in patients with residual or relapsed lymphoid malignancy following allogeneic haemopoietic stem cell transplantation","volume":"36","author":"Russell","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1053\/j.seminhematol.2011.03.009_bib35","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1182\/blood-2004-06-2275","article-title":"Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma","volume":"104","author":"Maris","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.03.009_bib36","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1182\/blood-2004-03-1105","article-title":"Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma","volume":"104","author":"Morris","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.03.009_bib37","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1182\/blood-2002-03-0701","article-title":"Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders","volume":"100","author":"Perez-Simon","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.03.009_bib38","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.bbmt.2010.04.006","article-title":"Outcome following reduced-intensity allogeneic stem cell transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation","volume":"16","author":"Cook","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1053\/j.seminhematol.2011.03.009_bib39","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.bbmt.2008.01.008","article-title":"Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome","volume":"14","author":"Armand","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1053\/j.seminhematol.2011.03.009_bib40","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S1083-8791(01)70016-X","article-title":"Allogeneic bone marrow transplantation in patients with sensitive low-grade lymphoma or mantle cell lymphoma","volume":"7","author":"Berdeja","year":"2001","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1053\/j.seminhematol.2011.03.009_bib41","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/CCO.0b013e3280148a43","article-title":"Blood or marrow transplantation for mantle cell lymphoma","volume":"19","author":"Kasamon","year":"2007","journal-title":"Curr Opin Oncol"},{"key":"10.1053\/j.seminhematol.2011.03.009_bib42","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.bbmt.2004.09.007","article-title":"Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphoma","volume":"11","author":"Kasamon","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1053\/j.seminhematol.2011.03.009_bib43","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1093\/annonc\/mdi107","article-title":"Hematopoietic stem cell transplantation in mantle cell lymphoma","volume":"16","author":"Ganti","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2011.03.009_bib44","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/ajh.20646","article-title":"Efficacy of high-dose therapy and hematopoietic stem cell transplantation for mantle cell lymphoma","volume":"81","author":"Laudi","year":"2006","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2011.03.009_bib45","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/j.bbmt.2006.08.035","article-title":"Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma","volume":"12","author":"Rodriguez","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1053\/j.seminhematol.2011.03.009_bib46","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/10428190400015022","article-title":"Allogeneic stem cell transplantation for mantle cell lymphoma\u2014does it deserve a better look?","volume":"46","author":"Rifkind","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2011.03.009_bib47","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.bbmt.2009.01.010","article-title":"Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-Hodgkin lymphomas","volume":"15","author":"Hamadani","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1053\/j.seminhematol.2011.03.009_bib48","unstructured":"Robinson SP, Taghipour G, Canals C, et al. Reduced-intensity conditioning and allogeneic stem cell transplantation in mantle cell lymphoma: update from the lymphoma working party of the EBMT. EBMT Meeting 2006. Hamburg, Germany; March 19-22, 2006."},{"key":"10.1053\/j.seminhematol.2011.03.009_bib49","unstructured":"Le Gouill S, Kr\u00f6ger N, Dhedin N, et al. Non-myeloablative allogeneic stem cell transplantation in mantle cell lymphoma. EBMT Meeting 2009. Goteborg, Sweden; March 29\u2013April 1, 2009."},{"key":"10.1053\/j.seminhematol.2011.03.009_bib50","doi-asserted-by":"crossref","unstructured":"Robinson SP, Schmitz N, Taghipour T, Sureda A. Reduced intensity allogeneic stem cell transplantation for mantle cell lymphoma is associated with substantial late transplant relapted mortality and a poor outcome in patients with chemoresistant disease [abstract 2260]. EBMT Meeting 2004. Barcelona, Spain; March 28\u201331, 2004.","DOI":"10.1182\/blood.V104.11.2260.2260"},{"key":"10.1053\/j.seminhematol.2011.03.009_bib51","doi-asserted-by":"crossref","first-page":"4310","DOI":"10.1182\/blood-2001-11-0107","article-title":"Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation","volume":"100","author":"Robinson","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.03.009_bib52","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.3058.3058","article-title":"Allogeneic stem cell transplantation with dose-reduced conditioning in relapsed follicular and mantle cell lymphoma\u2014a prospective phase II trial of the german low grade lymphoma study group [abstract]","volume":"110","author":"Dreyling","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.03.009_bib53","unstructured":"Gayoso J, Martino R, Balsalobre P, et al. Long-term results of fludarabine\/melphalan as reduced-intensity conditioning regimen in mantle cell lymphoma: age matters. EBMT Meeting 2009. Goteborg, Sweden; March 29\u2013April 1, 2009."},{"key":"10.1053\/j.seminhematol.2011.03.009_bib54","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/bmt.2008.12","article-title":"Rituximab as salvage therapy for refractory chronic GVHD","volume":"41","author":"Mohty","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1053\/j.seminhematol.2011.03.009_bib55","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S1083-8791(03)00216-7","article-title":"Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody","volume":"9","author":"Ratanatharathorn","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1053\/j.seminhematol.2011.03.009_bib56","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/cncr.20483","article-title":"The role of fludarabine in the treatment of follicular and mantle cell lymphoma","volume":"101","author":"Lenz","year":"2004","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2011.03.009_bib57","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"Forstpointner","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.03.009_bib58","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1182\/blood-2010-02-270538","article-title":"Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase 2 study","volume":"116","author":"Bethge","year":"2010","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.03.009_bib59","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1080\/10428190500260478","article-title":"Allogeneic hematopoietic cell transplantation following conditioning with 90Y-ibritumomab-tiuxetan","volume":"47","author":"Fietz","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2011.03.009_bib60","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2005.03.108","article-title":"Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma","volume":"23","author":"Goy","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2011.03.009_bib61","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1200\/JCO.2005.02.050","article-title":"Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma","volume":"23","author":"O'Connor","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2011.03.009_bib62","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1200\/JCO.2007.15.3429","article-title":"Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma","volume":"26","author":"Wiernik","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2011.03.009_bib63","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1182\/blood-2005-07-2845","article-title":"Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma","volume":"107","author":"Pott","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.03.009_bib64","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.1200\/JCO.2008.21.3116","article-title":"Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma","volume":"27","author":"Andersen","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2011.03.009_bib65","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.bbmt.2006.07.007","article-title":"Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma","volume":"12","author":"Ladetto","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1053\/j.seminhematol.2011.03.009_bib66","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1007\/s00259-010-1469-2","article-title":"Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group","volume":"37","author":"Bodet-Milin","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.seminhematol.2011.03.009_bib67","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1182\/blood-2007-06-093401","article-title":"Nuclear expression of the non B-cell lineage Sox11 transcription factor identifies mantle cell lymphoma","volume":"111","author":"Ek","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.03.009_bib68","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1182\/blood-2005-10-4079","article-title":"The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma","volume":"107","author":"Katzenberger","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.03.009_bib69","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S1535-6108(03)00028-X","article-title":"The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma","volume":"3","author":"Rosenwald","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1053\/j.seminhematol.2011.03.009_bib70","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1080\/10428190802216707","article-title":"Positron emission tomography in mantle cell lymphoma","volume":"49","author":"Brepoels","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2011.03.009_bib71","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.03.009_bib72","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1200\/JCO.2006.08.4251","article-title":"Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature","volume":"25","author":"Salaverria","year":"2007","journal-title":"J Clin Oncol"},{"issue":"Suppl 4","key":"10.1053\/j.seminhematol.2011.03.009_bib73","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/annonc\/mdn193","article-title":"Current treatment standards and future strategies in mantle cell lymphoma","volume":"19","author":"Dreyling","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2011.03.009_bib74","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1080\/10428190701851364","article-title":"Therapeutic options in mantle cell lymphoma","volume":"49","author":"Gill","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2011.03.009_bib75","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/sj.bmt.1705080","article-title":"Stem cell transplantation for mantle cell lymphoma: if, when and how?","volume":"36","author":"Kiss","year":"2005","journal-title":"Bone Marrow Transplant"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196311000369?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196311000369?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:21:36Z","timestamp":1758522096000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196311000369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":75,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["S0037196311000369"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2011.03.009","relation":{},"ISSN":["0037-1963"],"issn-type":[{"type":"print","value":"0037-1963"}],"subject":[],"published":{"date-parts":[[2011,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma: Where Are We Now and Which Way Should We Go?","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2011.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}